📬 GYN Oncology Intelligence Digest — Week 2026-W33
Ovarian ascites lipids blunt T-cell activation and argue for shorter CAR T manufacturing, GOG 3026 posts a 30.6% ORR with ribociclib plus letrozole in recurrent LGSOC, FIGO 2023 endometrial restaging fails to show superiority over FIGO 2009, KEYNOTE-B96 draws sequencing pushback, BI 1808 plus pembrolizumab gets FDA Fast Track, and PD-L1 IHC 22C3 pharmDx clears the EU as a companion diagnostic in platinum-resistant ovarian cancer.
⚡ TL;DR
🐦 Twitter / 🦋 Bluesky
- CD98hc-targeted antibody-drug conjugates enter the ovarian cancer target list alongside an ADC position statement — CD98hc-targeted antibody-drug conjugates exhibited potent anti-tumor activity in ovarian cancer, supporting CD98hc as a therapeutic target
- FDA grants Fast Track to BI 1808 plus pembrolizumab in advanced ovarian cancer — The FDA granted Fast Track designation to BI 1808 plus pembrolizumab for patients with advanced ovarian cancer
- KEYNOTE-B96: first positive checkpoint inhibitor in ovarian cancer, but clinicians question attribution and where it fits — KEYNOTE-B96 paired pembrolizumab with weekly paclitaxel plus bevacizumab, with bevacizumab not randomized and 73% receiving it by investigator choice, so the trial cannot separate the pembrolizumab effect from a pembrolizumab plus bevacizumab one
Full details below ↓
📄 What's Being Published
Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer. — Yang Zelei et al., Clin Cancer Res
Samples from 39 patients enrolled across two abemaciclib combination trials (NCT03675893) — testing letrozole/abemaciclib and letrozole/metformin/abemaciclib — were analyzed for RB1 and TP53 mutation status, RB protein expression, and RB function-predictive transcriptional signatures. RB protein expression levels and RB1 mutation status did not correlate with CDK4/6 inhibitor response; instead, decreased activity of multiple RB function-predictive transcriptional signatures, consistent with functional RB, corresponded to response. Reduced expression of specific E2F family members also correlated with CDK4/6 inhibitor response.
Clinical bottom line: Select endometrial cancer patients for CDK4/6 inhibitors by RB function-predictive transcriptional signatures rather than RB1 mutation status or RB protein staining.
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study. — Harano Kenichi et al., Clin Cancer Res
In this pilot study, ORR was 50.0% (95% CI, 18.7–81.3) with olaparib monotherapy in Cohort 1 and 70.0% (95% CI, 45.7–88.1) with olaparib plus pembrolizumab in Cohort 2 (p=0.2839). Within Cohort 2, ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non-BRCA1/2-mutated tumors. Olaparib monotherapy did not increase tumor immunogenicity, while the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes.
Clinical bottom line: Neoadjuvant olaparib produced measurable radiographic activity in HRD-positive advanced ovarian cancer, and adding pembrolizumab raised CD8+ T-cell infiltration without a clear gain in early clinical response.
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
CD98hc-targeted antibody-drug conjugates enter the ovarian cancer target list alongside an ADC position statement
CD98hc-targeted antibody-drug conjugates exhibited potent anti-tumor activity in ovarian cancer, advancing CD98hc as a therapeutic target under active evaluation. Separately, an ETOP IBCSG Partners Foundation position statement characterized antibody-drug conjugates as increasingly standard in ovarian and cervical cancers, with stated priorities that include carefully selecting trials for phase III, developing predictive biomarkers, optimizing ADC constructs and targets, and addressing biomarker heterogeneity. With FRα and TROP2 payloads already in the clinic, clinicians are debating what predictive biomarker would justify moving a CD98hc antibody-drug conjugate into ovarian cancer trials.
Discussed by: @sigtrans_sttt, @sigtrans-sttt.bsky.social
FDA grants Fast Track to BI 1808 plus pembrolizumab in advanced ovarian cancer
The FDA granted Fast Track designation to BI 1808 plus pembrolizumab for patients with advanced ovarian cancer, with BioInvent receiving the designation for BI-1808 for the treatment of ovarian cancer. The action was noted among the week's notable regulatory events. Specialists are considering whether a TNFR2-directed antibody added to pembrolizumab has a plausible path in ovarian cancer given how narrow single-agent checkpoint activity has been in this disease.
Discussed by: @OncLive, @Larvol, @onclive.bsky.social
KEYNOTE-B96: first positive checkpoint inhibitor in ovarian cancer, but clinicians question attribution and where it fits
KEYNOTE-B96 paired pembrolizumab with weekly paclitaxel plus bevacizumab, but bevacizumab was not randomized — 73% of patients received it by investigator choice — meaning the trial cannot separate the pembrolizumab effect from a pembrolizumab plus bevacizumab one. The regimen is labeled at 1 to 2 prior lines with CPS≥1, with a 1.1 month PFS gain and added immune toxicity, while established platinum-resistant options include mirvetuximab (OS 16.9 vs 13.3 months, HR 0.68) for FRα-positive patients and relacorilant plus nab-paclitaxel (OS 16.0 vs 11.9 months, HR 0.65) with no biomarker required. PD-L1 IHC 22C3 pharmDx has now gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer, sharpening debate over whether pembrolizumab holds a sequencing slot ahead of mirvetuximab or relacorilant in that setting.
Discussed by: @DrBarbiOnc, @OncLive, @onclive.bsky.social
🔥 Top Ranked Tweets
ClinicalOncologyNews @ClinOncNews
KEYNOTE-C93 is the first phase 3 trial showing a PD-1 inhibitor alone improved PFS over chemotherapy in front-line dMMR advanced/recurrent endometrial cancer—potentially changing treatment options: https://t.co/arI33n8etK #EndometrialCancer #oncology https://t.co/RRmeNTMXnu
🔖 0 ❤️ 1 🔁 0 👁 81
ClinicalOncologyNews @ClinOncNews
Pembrolizumab beat platinum chemo on PFS in untreated dMMR endometrial cancer (KEYNOTE-C93), pointing to a chemo-free frontline option. Full data pending. #EndometrialCancer #Immunotherapy #Keytruda #Oncology #PD1
https://t.co/arI33n8etK https://t.co/RqugfkN3ng
🔖 0 ❤️ 0 🔁 0 👁 94
Dr. Patrick Hwu @PatrickHwuMD
❓ What if T cells are not failing because they are exhausted, but because they cannot properly switch on in the first place?
➡️ In advanced ovarian cancer, fluid called ascites can build up in the abdomen. This fluid creates a complex tumor environment filled with cancer cells, immune cells and unusually high levels of fats, or lipids.
Researchers found that some of these lipids can interfere with T cells, the immune cells responsible for recognizing and attacking cancer.
➡️ Normally, receptors on the surface of a T cell gather into tiny clusters when they recognize a threat. This clustering acts like an alarm, activating the T cell so it can multiply, produce cancer-killing molecules and attack its target.
But in ovarian cancer ascites, lipids altered the T cell’s outer membrane and disrupted how those receptors moved, clustered and recycled back to the cell surface. The T cells remained alive, but their activation signal was weakened before they could fully respond.
➡️ The researchers identified one lipid, called 18:0–18:2 phosphatidylcholine, that reduced T-cell activation, growth and cancer-killing ability at levels similar to those found in patient ascites.
When the researchers removed lipids from the fluid, T-cell signaling and function improved, suggesting that these fats are an important part of the immune-suppressing environment.
➡️ The team also discovered a potential way around this barrier: T cells that were already actively stimulated before entering the ascites continued to function much better.
In laboratory experiments, recently activated #CART cells maintained their cancer-killing ability, while older CAR T cells that had returned to a resting state were more easily suppressed.
💡 Why this matters: This study provides a new explanation for why T-cell therapies have struggled against ovarian cancer. Rather than simply exhausting or killing T cells, tumor-associated lipids may prevent them from properly switching on in the first place.
The findings also suggest that shortening the CAR T-cell manufacturing process, so the cells are infused while they are still highly active, could help them resist this lipid-rich environment.
✨ The big takeaway: The environment around a tumor can be just as important as the cancer itself. By understanding how ovarian cancer ascites blocks T-cell activation, researchers may be able to design stronger and more effective cellular therapies. @DJPowellLab @Pennmedicine @Nature @RoddyOConnor @carlhjune @MichaelLDustin @KirOxford @Princeton @UMNews @UniofOxford @PennMedNews @PennMDForum @Penn
🔗 Read the study: https://t.co/TfdZaZJl4z
🔖 57 ❤️ 99 🔁 16 👁 5,590
Elad Sharon @EladSharonMD
RT @PatrickHwuMD: ❓ What if T cells are not failing because they are exhausted, but because they cannot properly switch on in the first place?
➡️ In advanced ovarian cancer, fluid called ascites can build up in the abdomen. This fluid creates a complex tumor environment filled with cancer cells, immune cells and unusually high levels of fats, or lipids.
Researchers found that some of these lipids can interfere with T cells, the immune cells responsible for recognizing and attacking cancer.
➡️ Normally, receptors on the surface of a T cell gather into tiny clusters when they recognize a threat. This clustering acts like an alarm, activating the T cell so it can multiply, produce cancer-killing molecules and attack its target.
But in ovarian cancer ascites, lipids altered the T cell’s outer membrane and disrupted how those receptors moved, clustered and recycled back to the cell surface. The T cells remained alive, but their activation signal was weakened before they could fully respond.
➡️ The researchers identified one lipid, called 18:0–18:2 phosphatidylcholine, that reduced T-cell activation, growth and cancer-killing ability at levels similar to those found in patient ascites.
When the researchers removed lipids from the fluid, T-cell signaling and function improved, suggesting that these fats are an important part of the immune-suppressing environment.
➡️ The team also discovered a potential way around this barrier: T cells that were already actively stimulated before entering the ascites continued to function much better.
In laboratory experiments, recently activated #CART cells maintained their cancer-killing ability, while older CAR T cells that had returned to a resting state were more easily suppressed.
💡 Why this matters: This study provides a new explanation for why T-cell therapies have struggled against ovarian cancer. Rather than simply exhausting or killing T cells, tumor-associated lipids may prevent them from properly switching on in the first place.
The findings also suggest that shortening the CAR T-cell manufacturing process, so the cells are infused while they are still highly active, could help them resist this lipid-rich environment.
✨ The big takeaway: The environment around a tumor can be just as important as the cancer itself. By understanding how ovarian cancer ascites blocks T-cell activation, researchers may be able to design stronger and more effective cellular therapies. @DJPowellLab @Pennmedicine @Nature @RoddyOConnor @carlhjune @MichaelLDustin @KirOxford @Princeton @UMNews @UniofOxford @PennMedNews @PennMDForum @Penn
🔗 Read the study: https://t.co/TfdZaZJl4z
🔖 57 ❤️ 99 🔁 16 👁 5,589
MV Chandrakanth @ChandrakanthMv
Ribociclib + Letrozole: A New Benchmark in Recurrent LGSOC?
The phase II GOG 3026 trial adds to the growing evidence supporting CDK4/6 inhibition in recurrent low-grade serous ovarian cancer.
Key findings
• ORR: 30.6% (1 CR, 14 PR)
• Clinical benefit rate: 84%
• Median duration of response: 21.2 months
• Median PFS: 14.5 months
• Primary endpoint successfully met (15 responses observed; ≥8 required)
Clinical perspective
• Durable responses were observed despite inclusion of patients across multiple prior lines of therapy.
• Reinforces the biologic rationale for combining endocrine therapy with CDK4/6 inhibition in ER-positive LGSOC.
• Although encouraging, these results come from a single-arm phase II study and await confirmation in randomized trials.
Slomovitz et al. JCO 2026.
#LGSOC #OvarianCancer #GynOnc #CDK46 #Ribociclib #Letrozole #MedicalOncology #JCO #MVOnco
🔖 11 ❤️ 37 🔁 14 👁 2,122
ACS Journal Cancer @JournalCancer
New review article by @harvardmed @DanaFarber @BIDMChealth discusses current maintenance therapy practices, emerging areas of research, and challenges in gynecologic malignancies.
🔗: https://t.co/CFNyZYsY9m
@OncoAlert #gyncsm https://t.co/jdQRdTdUQ5
🔖 8 ❤️ 15 🔁 10 👁 1,911
OncoAlert @OncoAlert
RT @scocmem: Important RWD in the emerging post-EVP era: ORR 49% with platinum chemo @ESMO_Open
74% had carbo with similar outcomes – reassuring given post-EV neuropathy limiting cis.
20% got avelumab – prospective trials are testing ICI rechallenge.
@OncoAlert
https://t.co/J1i7uNgAju https://t.co/FgMfN4dwnX
🔖 6 ❤️ 25 🔁 13 👁 2,935
Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc
Today I reviewed #KEYNOTE_B96 with my fellow. Two questions. Why is this the first ICI that works in #ovariancancer, and where do I sequence it.The first is design, not the drug. B96 pairs pembro with an active backbone, weekly paclitaxel plus bev, and bev was not randomized. 73% got it by investigator choice. So the trial cannot separate the pembro effect from a pembro plus bev one. The PFS benefit shows up regardless of PD-L1. We may be crediting the checkpoint for what the backbone and bev did. >> The second question is where I get stuck. In #platinum_resistant disease I test FRα first. If positive, that is #mirvetuximab, OS 16.9 vs 13.3, HR 0.68. If negative, #relacorilant plus nab-paclitaxel, no biomarker needed, OS 16.0 vs 11.9, HR 0.65. Or a trial.
B96 is labeled at 1 to 2 prior lines, CPS≥1, with a 1.1 month PFS gain and added immune toxicity. Every patient who fits it already has a cleaner, better-targeted option ahead of it. First positive ICI in ovarian, unclean attribution, and no slot to sequence it.
#gyncsm #OncTwitter
https://t.co/fftezopDhb
🔖 4 ❤️ 26 🔁 5 👁 1,559
Solange Peters @peters_solange
RT @OncoAlert: ADCs 💊 are already changing cancer treatment—but are we getting the next generation right?
Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
This position paper summarizes expert recommendations for advancing antibody–drug conjugate (ADC) research and clinical use across solid tumors. ADCs are increasingly standard treatments in #LungCancer 🫁 , #BreastCancer, #BladderCancer, #OvarianCancer, and #CervicalCancers. Priorities include carefully selecting trials for phase III, developing predictive biomarkers, optimizing ADC constructs and targets, and addressing biomarker heterogeneity. The experts also highlight artificial intelligence as a potential tool to integrate complex datasets and accelerate discovery of composite biomarkers.
@peters_solange
@BanerjeeSusana
@curijoey
@niklas_kluemper
@g_mountzios
@LuisPaz_Ares
@BarbaraPistill2
@tompowles1
@NReguart
@LizzySmyth1
@CharlesSwanton
@LoiSher
@TobiasSchmelzle
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
🔖 3 ❤️ 17 🔁 9 👁 2,550
Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc
Heading to #NRG2026 this weekend, so this feels timely.
#KEYNOTEC93 met its PFS endpoint: pembro monotherapy beat carbo/paclitaxel frontline in dMMR #EndometrialCancer (Merck, July 15, 2026). Real result, but the comparator is chemo alone, not chemo+IO. The #GY018 and #RUBY already moved #dMMR to chemo+IO (HR ~0.30-0.35). Beating chemo alone isn’t the same as matching chemo+IO.
The real clinical question is sequencing: IO first, chemo held in reserve? or chemo+IO first, since pembro (and pembro/lenva) are already approved post-progression regardless of arm. PFS1 doesn’t answer that. PFS2 would, if it was pre-specified and if post-progression therapy was tracked cleanly by arm - neither is confirmed yet.
OS immature, no HR/curves released. Still, a genuine step forward for a chemo-free option in the right patients, and a good sign of how fast this field is moving. Looking forward to digging into the details at NRG.
Merck, July 15, 2026 (KEYNOTE-C93, NCT05173987).
#gyncsm
@NRGonc
🔖 3 ❤️ 3 🔁 0 👁 438
IJGC @IJGConline
Phase 3 KEYNOTE-C93 trial results!🔥🔥
#EndometrialCancer
[Quoting @OncoAlert: NEWS FROM INDUSTRY: KEYNOTE-C93 Update in #EndometrialCancer
Source: Merck press release
The Phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent endometrial cancer with mismatch repair deficient (dMMR) tumors. The study demonstrated meaningful response rates, complete responses, and durable responses, with a safety profile consistent with prior pembrolizumab studies. Results suggest a potential chemotherapy-free frontline treatment option for this patient population.
https://t.co/1eUPTPKiNh
@agz_eriksson
@ESGO_society
@IJGConline
@NicoloBizzarri
@nataliagandur
@realbowtiedoc
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@amandaNizamMD
@DrVilmaPBarcia]
🔖 2 ❤️ 8 🔁 5 👁 2,091
OncLive.com @OncLive
📋 BEHOLD-2 is enrolling patients with MMR-proficient/MSS endometrial cancer who progressed on prior therapy. Angeles Alvarez Secord, MD, MHSc explains why pairing a B7-H4 ADC with dostarlimab could reach tumors immunotherapy alone can't.
▶️ Watch now: https://t.co/i3p5tmUQTp
@AngelesSecord @DukeHealth #EndometrialCancer #ClinicalTrials #ImmunoOncology
🔖 2 ❤️ 4 🔁 0 👁 1,658
OncoAlert @OncoAlert
RT @IJGConline: #LeadArticle #RUBYtrial 💎 part 2!
Niraparib in patients with primary advanced or recurrent #endometrialcancer receiving dostarlimab ➕ chemotherapy
📌 https://t.co/othPkgSrCr
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde
🔖 1 ❤️ 15 🔁 6 👁 2,249
IJGC @IJGConline
#LeadArticle #RUBYtrial 💎 part 2!
Niraparib in patients with primary advanced or recurrent #endometrialcancer receiving dostarlimab ➕ chemotherapy
📌 https://t.co/othPkgSrCr
@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde
🔖 1 ❤️ 15 🔁 6 👁 2,249
IJGC @IJGConline
#WeeklyRoundup
👩⚕️ #GynOncology
✅Node Boost in Stage IIIC #CervicalCancer
[Quoting @OncoAlert: The OncoAlert WEEKLY RoundUp 🚨 #ESMO25
Covering the TOP of the week October 10-17, 2025
REGISTER at https://t.co/QFM2SYXqbg OR https://t.co/hwvqbilbLO
Discussing:
🧬 #BreastCancer
✅HER2CLIMB-05 Update (Pfizer)
Tucatinib + trastuzumab/pertuzumab in 1L maintenance for HER2+ MBC significantly improved PFS vs placebo with consistent safety.
👉 May redefine 1L maintenance, further delaying progression.
✅KEYNOTE-119 Biomarker Analysis (Cortes J, Winer E, npj Breast Cancer)
In mTNBC, pembrolizumab response correlated with higher TILs, T-cell–inflamed GEP, and TMB — but not BRCA or HRD status.
👉 Immunogenic biomarkers predict benefit to pembrolizumab.
✅Early Breast Cancer in Young BRCA Carriers (Ther Adv Med Oncol)
Review highlights the need for personalized, multidisciplinary care—surveillance, fertility, PARP inhibitors, and survivorship focus.
👉 Tailored management essential for young BRCA1/2 carriers.
🫁 #LungCancer
PACIFIC-2 Trial
✅Concurrent durvalumab + chemoradiotherapy in unresectable stage III NSCLC did not improve PFS or OS vs placebo.
👉 Consolidation durvalumab after cCRT remains the SOC.
✅Osimertinib + Consolidative RT in EGFR-mutant NSCLC (eClinical Medicine)
Adding consolidative RT after response to osimertinib achieved PFS 32.3 mo and OS 45 mo with good safety.
👉 Promising durable control—supports randomized evaluation.
GI Oncology
✅Neoadjuvant ICI vs FLOT in dMMR/MSI-H GEA (Raimondi A, JCO)
ICIs achieved pCR 61.9% vs 3.7% with FLOT and better downstaging; survival similar.
👉 ICIs show superior pathologic response—supporting organ-sparing approaches.
GU Oncology
✅Metastasis-Directed RT Without Systemic Therapy in RCC (Lancet Oncology) #KidneyCancer
In oligometastatic ccRCC, MDT achieved PFS 17.7 mo and systemic therapy-free survival 34 mo with low toxicity.
👉 MDT alone can delay systemic therapy with durable control.
✅Salvage Brachytherapy for Locally Recurrent #ProstateCancer (Green Journal / ESTRO)
Largest cohort (n=266): median bPFS 40 mo; high-risk disease, HDR, focal BT, and ADT linked to worse outcomes.
👉 Salvage BT offers feasible control with acceptable late toxicity.
👩⚕️ Gyn Oncology
✅Node Boost in Stage IIIC #CervicalCancer (IJGC)
Radiotherapy boost to positive nodes improved OS (107 vs 91 mo), especially in patients with smaller/fewer nodes.
👉 Nodal boost improves survival in selected patients.
Reirradiation Across Tumor Types (CA: A Cancer Journal for Clinicians)
#RadOnc ☢️
✅Advances in IMRT/SBRT make reRT viable but high-risk—requires careful selection, imaging, and multidisciplinary input.
👉 Reirradiation offers opportunity for control with thoughtful planning.
And much more!
@DrSAHaddad
@ErikaHamilton9
@SuyogCancer
@DrHBurstein
@UOzkerim
@LoiSher
@RobertoBoreaMD
@matteolambe
@drjkyl
@DrJNaidoo
@HenningWillers
@StephenVLiu
@DrRishabhOnco
@M_Torasawa
@SawsanRashdanMD
@raquel_ciervide
@Tony_Calles
@HerediaOncologo
@TeWilliamsMD
@GIMedOnc
@UGrewalMD
@DraMartinezLago
@dr_JhPark
@ChadTangMD
@PavlosMsaouel
@changjeesuk1
@_ShankarSiva
@davidjeinstein
@PBlanchardMD
@ColtonLadbury
@APCCC_Lugano
@ArmandoFelix70
@LuisAlberto3P
@David__Pasquier
@AlexisNarvaezMD
@Icro_Meattini
@BenWestphalen
@OncBrothers]
🔖 1 ❤️ 4 🔁 1 👁 1,173
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.